Should SARS CoV-2 Infection be Considered an Independent Risk Factor
for Pneumocystis jirovecii Pneumonia? Emerging Data after Two Years of
Pandemic from a Single Center Experience

Antonio   Riccardo   Buonomo; Giulio      Viceconte; Biagio      Pinchera; Riccardo      Scotto; Emanuela      Zappulo; Maria      Foggia; Ivan      Gentile

doi:10.2174/1574887117666220511123826

« Previous

[1]
Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis. Clin Microbiol Infect  2020; 26(12): 1622-9.
 [http://dx.doi.org/10.1016/j.cmi.2020.07.016] [PMID: 32711058]

[2]
Casalini G, Giacomelli A, Ridolfo A, Gervasoni C, Antinori S. Invasive fungal infections complicating COVID-19: A narrative review. J Fungi (Basel)  2021; 7(11): 921.
 [http://dx.doi.org/10.3390/jof7110921] [PMID: 34829210]

[3]
Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis  2020; 71(6): 1367-76.
 [http://dx.doi.org/10.1093/cid/ciz1008] [PMID: 31802125]

[4]
Gentile I, Viceconte G, Lanzardo A, et al. Pneumocystis jirovecii pneumonia in Non-HIV patients recovering from COVID-19: A single-center experience. Int J Environ Res Public Health  2021; 18(21): 11399.
 [http://dx.doi.org/10.3390/ijerph182111399] [PMID: 34769913]

[5]
Viceconte G, Buonomo AR, Lanzardo A, et al. Pneumocystis jirovecii pneumonia in an immunocompetent patient recovered from COVID-19. Infect Dis (Lond)  2021; 53(5): 382-5.
 [http://dx.doi.org/10.1080/23744235.2021.1890331] [PMID: 33645461]

[6]
Del Corpo O, Butler-Laporte G, Sheppard DC, Cheng MP, McDonald EG, Lee TC. Diagnostic accuracy of serum (1-3)-β-D-glucan for Pneumocystis jirovecii pneumonia: A systematic review and meta-analysis. Clin Microbiol Infect  2020; 26(9): 1137-43.
 [http://dx.doi.org/10.1016/j.cmi.2020.05.024] [PMID: 32479781]

[7]
Buonomo AR, Viceconte G, Gentile I. Pneumocystis jirovecii pneumonia in COVID-19: An overlooked clinical entity-Response to “Pneumocystis pneumonia risk among viral acute respiratory distress syndrome related or not to COVID 19”. Crit Care  2021; 25(1): 418.
 [http://dx.doi.org/10.1186/s13054-021-03836-7] [PMID: 34872608]

Rights & Permissions Print Cite

Article Metrics

26

2

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1574887117666220511123826	Print ISSN 1574-8871
Publisher Name Bentham Science Publisher	Online ISSN 1876-1038

Reviews on Recent Clinical Trials

Should SARS CoV-2 Infection be Considered an Independent Risk Factor for Pneumocystis jirovecii Pneumonia? Emerging Data after Two Years of Pandemic from a Single Center Experience

Related Journals

Related Books

Related Articles